Former Intermountain Health executive Marc Harrison, MD, is transitioning from CEO of Health Assurance Transformation Corp. to a strategic advisor role, effective July 31, a spokesperson confirmed to Becker’s.
Daryl Tol will be promoted to president of HATCo, with the role also effective that same day.
The leadership shifts come as General Catalyst, a venture capital firm, advances its acquisition of Akron, Ohio-based Summa Health. General Catalyst agreed in November 2024 to purchase the two-hospital system for $485 million as part of HATCo and transform the health system into a for-profit entity. Dr. Harrison served as president and CEO of Intermountain Health from 2016 to 2022 before becoming CEO of HATCo in 2023.
Now is the right time for Dr. Harrison’s transition to an advisory role, HATCo spokesperson Molly Gillis said in a statement shared with Becker’s.
“The vision for HATCo and our partnership with Summa Health is tremendously ambitious, matched only by the positive impact we intend to make for the future of healthcare,” Ms. Gillis said. “As the strategy for HATCo has appropriately evolved to meet those ambitions, it became increasingly clear to both Marc and to us that Marc’s role would best be accomplished as a strategic advisor to [General Catalyst CEO] Hemant Taneja as we bring that ambition and vision to life.”
She added that the change allows Dr. Harrison “to provide his clinical point of view on macro trends in our industry as we enter this next very important phase of our journey to make health assurance a reality for all. [W]e look forward to leveraging his invaluable perspective as we continue to progress.”
HATCo, in announcing the transition, also shared that Mr. Tol, who has been leading HATCo’s transformation and integration efforts on the ground in Akron, was recently promoted to president of HATCo. Mr. Tol is former president and CEO of AdventHealth’s Central Florida Division.
HATCo is targeting the fourth quarter of 2025 to finalize the transaction.
As president of HATCo, Mr. Tol will continue to spearhead day-to-day collaboration with Summa leadership and the General Catalyst/HATCo team to ensure a successful transition, said Ms. Gillis.
She said Mr. Tol will also serve as a liaison into the General Catalyst health assurance ecosystem, “which he leads, to merge the best ideas, processes, and technologies from emerging entrepreneurs and forward-thinking healthcare systems.”
Meanwhile, former Boston Medical Center CEO Kate Walsh, who recently stepped down as Massachusetts HHS secretary, will serve as chairperson of the board for Summa Health post-close of the transaction, and as an HATCo board member.
“Kate brings a wealth of knowledge and experience, and we couldn’t be more excited to partner with her on this next evolution for both Summa Health and HATCo,” Ms. Gillis said.
